Navigation Links
Rochester Medical Corporation Announces Agreement to Acquire Laprolan B.V.
Date:1/12/2011

STEWARTVILLE, Minn., Jan. 12, 2011 /PRNewswire/ -- Rochester Medical Corporation (Nasdaq: ROCM) today announced it had reached an agreement with Fornix N.V. to purchase from Fornix its wholly owned subsidiary Laprolan B.V., a medical supplies distribution company located in Beuningen, The Netherlands.  Laprolan distributes wound care, ostomy care and urology products into the Dutch market and had unaudited revenues of approximately euro 8.0 million (approximately $10.5 million) in calendar 2010.

Under the agreement, Rochester Medical will pay approximately euro 10.35 million (approximately $13.73 million) in cash for the shares of Laprolan B.V.  The transaction is subject to approval by the shareowners of Fornix N.V., which will convene an extraordinary general meeting of shareholders for such purpose as soon as possible with the aim to complete the transaction soon thereafter.  The transaction is expected to close at the latest by May 31, 2011, but will have a retroactive effective date of January 1, 2011.  

Commenting on today's announcements, Rochester Medical CEO and President Anthony J. Conway said, "This acquisition when completed fits nicely with our ongoing plan to expand our direct branded presence in mainland Europe.  Laprolan has provided quality products and service to its customers in the Netherlands for 25 years, including Rochester Medical's products for the past 16 years.  Laprolan has distribution rights to market leading products in wound care, ostomy care and urology products in the Netherlands and its product lines and sales presence are a welcome addition to the Rochester Medical product offering and team."

Conway concluded, "I am extremely pleased with this opportunity for Rochester Medical, and we look forward to completing this acquisition and making it a successful part of our future."

Rochester Medical plans to discuss the acquisition of Laprolan further during its first quarter 2011 earnings conference call scheduled for January 25, 2011.

This press release contains "forward-looking statements" with the meaning of the Private Securities Litigation Reform Act of 1995.  Such statements include, but are not limited to, statements about the expected completion of the acquisition and financial results of Laprolan.  Such statements are based on currently available information, operating plans and management's expectations about future events and trends.  Such statements inherently involve significant risks and uncertainties that could cause actual results to differ materially from those predicted in such forward-looking statements, including the uncertainty of estimated revenues and profits, the uncertainty of current economic conditions, and other risk factors listed from time to time in the Company's SEC reports and filings, including, without limitation, the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended September 30, 2010.  Readers are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made.  The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Rochester Medical Corporation develops, manufactures, and markets disposable medical catheters and devices for urological and continence care applications.  The Company markets under its own Rochester Medical® brand and under existing private label arrangements.

For further information, please contact Anthony J. Conway, President and Chief Executive Officer or David A. Jonas, Chief Financial Officer of Rochester Medical Corporation at (507) 533-9600.  More information about Rochester Medical is available on its website at http://www.rocm.com.  More information about Laprolan B.V. is available at www.laprolan.nl.  


'/>"/>
SOURCE Rochester Medical Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Rochester Medical Reports Fourth Quarter and Year-End Results
2. Rochester Medical Announces Fourth Quarter 2010 Earnings Conference Call Thursday, November 4, 2010
3. AstraZeneca Joins Rochester Initiative to Further Cardiac Safety
4. Rochester Medical Corporation Honored by Premier Healthcare Alliance for Exceptional Supplier Performance
5. Rochester Medical Announces First Quarter 2010 Earnings Conference Call Tuesday, January 26, 2010
6. Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert
7. Rochester Medical Announces Fourth Quarter 2009 Earnings Conference Call Thursday, November 5th 2009
8. University of Rochester Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society
9. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
10. Solta Medical, Inc. Appoints Thomas J. Yorkey, Ph.D. to Vice President of Research & Development
11. DST HealthCare Launches Medical Drug Management Service™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2016)... 23, 2016 DS Biopharma ... and anti-inflammatory compound DS102 in chronic obstructive pulmonary ... steatohepatitis (NASH) patients. Recent DS preclinical ... lung tissue and has bronchodilatory, anti-inflammatory and anti-fibrotic ... The Company will publish further detail on these ...
(Date:5/20/2016)... ReportsnReports.com adds "Plaque Psoriasis ... research report with comprehensive information on the therapeutic ... comparative analysis at various stages, therapeutics assessment by ... administration (RoA) and molecule type, along with latest ... also reviews key players involved in the therapeutic ...
(Date:5/19/2016)... Oregon , May 19, 2016 ... titled, World Medical/Diagnostic Imaging Market -Opportunities and Forecasts, 2015 ... reach $45.0 billion by 2022, registering a CAGR of ... expected to continue to be the highest revenue-generating segment ... accounted for around one-third of the market share ...
Breaking Medicine Technology:
(Date:5/23/2016)... Bensonhurst, NY (PRWEB) , ... May 23, 2016 , ... ... Enrico Ferdico took the time to summarize the weight loss process: , New patients ... a Body Composition Analysis (BCA) to get accurately evaluated. , Body Composition Analysis, There ...
(Date:5/23/2016)... , ... May 23, 2016 , ... According to an article published May ... massive role in oral health and hygiene. The article points out that, as long as ... their toothbrushes will become worn and frayed. Of course, these worn-out bristles won’t clean teeth ...
(Date:5/23/2016)... , ... May 23, 2016 , ... According to an ... in an exuberant mood since the birth of her son, Rockwell Lloyd Liu, and ... ever had.” The “Elementary” and “Kill Bill” star explains that, as a career oriented ...
(Date:5/23/2016)... ... May 23, 2016 , ... The Clinical Data ... from the Japan PMDA, US FDA, industry and academia at the 2016 ... format data from clinical trials so that it can be shared and compared, ...
(Date:5/23/2016)... ... ... NYDNRehab, a New York City-based physical therapy clinic , is introducing ... type of technology, which was developed by world-renowned researcher Dr. Christopher Powers of University ... With over 10 million sport injuries per year in the United States, ...
Breaking Medicine News(10 mins):